RFA-DK-01-008: ROLE OF HORMONES AND GROWTH FACTORS IN PROSTATE CANCER

Department of Health
and Human Services (HHS)

NIH... Turning Discovery Into Health^®

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.

ROLE OF HORMONES AND GROWTH FACTORS IN PROSTATE CANCER Release Date: August 7, 2000 RFA: DK-01-008 National Institute of Diabetes and Digestive and Kidney Diseases (http://www.niddk.nih.gov/) National Institute on Aging (http://www.nih.gov/nia/) National Cancer Institute (http://www.nci.nih.gov/) National Institute of Environmental Health Sciences (http://www.niehs.nih.gov/) Letter of Intent Receipt Date: 2/27/01 Application Receipt Date: 3/27/01 PURPOSE This initiative is designed to explore the underlying mechanism(s) of action of hormones and growth factors in the regulation of prostate development, growth, and tumorigenesis. The focus will be on fundamental studies of hormone and growth factor action including the mechanisms of action of nuclear hormones, the role(s) of nuclear accessory proteins and the signal transduction pathways important for nuclear hormone action in prostate. Focus will also be on growth factor action in prostate, including growth factors, binding proteins, receptors and signal transduction pathways. Studies are also invited that will examine the patterns of gene expression in the prostate in vivo or in prostate cells in response to hormone or growth factor action. Moreover, since there are some studies that indicate that environmental factors also increase the risk for development of prostate cancer, an additional focus will be on studies that will explore the role of environmental factor(s) in affecting hormonal/growth factor action in prostate. Finally, studies on the development and potential use of hormone/growth factor analogs, agonists, or antagonists with potential clinical utility to modify prostate growth and tumor development and/or progression will be encouraged. HEALTHY PEOPLE 2010 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. {This RFA, ROLE OF HORMONES AND GROWTH FACTORS IN PROSTATE CANCER, is related to the priority area of hormonal carcinogenesis and prostate disease. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople. ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and nonprofit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) research project grant (R01) and pilot and feasibility (R21) award mechanisms. Only new (Type 1) grant submissions will be accepted for this initiative. Amended and competing continuing applications will not be accepted. Applications for research project grants (R01) may be submitted for up to 4 years of support with first year direct cost budgets of no more than $225,000. Applications for pilot and feasibility (R21) awards may be submitted for up to two years with first year direct cost budgets of no more than $100,000. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Except as otherwise stated in this announcement, awards will be administered under NIH grants policy as stated in the NIH Grants Policy Statement. Specific application instructions have been modified to reflect "MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts being examined by the NIH. Complete and detailed instructions and information on Modular Grants can be found at http://grants.nih.gov/grants/funding/modular/modular.htm. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. In such a case, a letter of agreement from either the GCRC program director or principal investigator should be included with the application. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total requested project period for applications submitted in response to this RFA may not exceed four years (two for the R21). The anticipated award date is September 28, 2001. FUNDS AVAILABLE For FY 2001, $3,000,000 will be committed by NIDDK to fund applications submitted in response to this RFA. The NIA will commit $300,000, the NCI will commit $1,000,000, and NIEHS will commit $300,000. Thus, a total of $4,600,000 has been committed for FY 2001 to fund approximately 20-25 grants, however, this funding level is dependent upon the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NIDDK, NIA, NCI, and NIEHS, the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background Although the prostate is clearly a sex steroid (Androgen) dependent tissue, there is ample evidence to support roles for numerous other nuclear and peptide hormones, as well as growth factors and cytokines in the development of the tissue and the development and progression of tumors arising from cells within the adult tissue. At a recent NIDDK International Symposium on the Biology of Prostate Growth, data were presented to show that factors such as the Insulin-like growth factor-I (IGF-I), fibroblast growth factor (FGF), members of the erbB family, and others, as well as their receptors and binding proteins, and other small bioactive peptide hormones, have been implicated in development, growth and differentiation of both the epithelial and the stromal components of prostate. Furthermore, activation of peptide growth factor receptors initiates signal transduction pathways leading to change in cellular function and/or structure. In some cases of aberrant prostate growth, the growth factor receptors are overexpressed or otherwise dysregulated, or are constitutively activated. In other cases, components of signal transduction pathways are overexpressed or constitutively activated. Additionally, agents that block receptor activation and/or signaling are becoming available for use in analysis and/or treatment of tumors. The contribution of growth factors, such as IGF-I, their receptors, binding proteins and signaling pathways in the development and/or progression of tumors needs further investigation. Eicosanoids (prostaglandins) are another class of mediators that may also contribute to prostate growth and differentiation. Expression of the inducible form of one enzyme responsible for prostaglandin synthesis, cyclooxygenase 2 (COX-2), has been observed in prostate cancer. Pharmacologic inhibition of COX-2 activity induces apoptosis in prostate cancer cells. Further, some prostaglandins act through the peroxisome proliferator-activated receptor (PPAR), a member of the nuclear hormone superfamily. The recent availability of COX-2 inhibitors and PPAR agonists will allow a sophisticated analysis of their contributions to prostate growth and tumorigenesis. Still other cytokines and growth factors, including interleukin (IL)-6, members of the transforming growth factor (TGB)-beta family, and others, have also been implicated in the development of prostate cancer. New insights into the molecular mechanism(s) of action of such factors through the cytokine receptor superfamily and transcription factors such as the Smad proteins may have relevance to prostate growth and or disease, as well. While growth factors are extremely important in prostate function, members of the nuclear hormone superfamily play crucial roles in prostate development, growth, function, and tumorigenesis and/or progression. Studies in developing prostate are of interest since signaling pathways present at that time may have important implications for later development of tumors. The receptors for the nuclear receptor superfamily function primarily as transcription factors in the nucleus to either suppress or activate gene expression through effects on DNA transcription. At a recent NIDDK workshop entitled Co- activators and Co-repressors in Gene Expression, work was presented which suggested a role for the relative affinity of binding of nuclear accessory proteins, including co-repressors and co-activators, to form complexes essential to determining whether a particular gene is activated or not in response to hormone. Further observations have pointed to mutations in nuclear accessory proteins and/or nuclear receptors as factors that can either cause hormone resistance or inappropriate gene expression. Fusion proteins, which cause cancers, such as the acute myelogenous leukemia-eight to twenty-one (AML-ETO) fusion protein in acute myelogenous leukemia, recruit co-repressor complexes to block gene transcription relevant to differentiation of hematopoietic precursors. These factors have now become targets for therapeutic intervention, as well. In addition, mutations in one co- activator, known as AIB1, a member of the steroid receptor coactivator (SRC)-1 family, have been implicated in breast cancer. Androgens represent the primary steroid hormone affecting gene expression in the prostate, though roles for estrogen and for orphan nuclear receptors have also been suggested. Indeed, studies on the newly discovered estrogen receptor (ER)-beta have revealed high levels in prostate tissue, with the intriguing suggestion of a role(s) in prostate development, as well as in prostate hyperplasia. Androgens appear to form homodimer pairs in binding to chromatin, and recruit nuclear accessory proteins, such as androgen receptor associated (ARA) 70 protein. The ARA is thus also a candidate for interaction with other nuclear accessory proteins, such as co-activators or co- repressors that regulate repression or activation of target genes. Finally, orphan nuclear receptors--proteins structurally consistent with nuclear receptors but for which no known hormone exists--have been shown to have functions in prostate, as well (e.g., chicken ovalbumin upstream transcription factor, or COUP-TF, and testis associated receptor, or TR4). Another recent NIH Workshop on Selective Estrogen Receptor Modulators (SERMS), focused on the potential utility of hormonal analogs, partial agonists, and antagonists as therapeutic agents for hormonal-dependent cancers, including those in breast and prostate. Some of these Selective Receptor Modulators (SRM"s) have already found their way into clinical use in the treatment and/or prevention of breast cancer (e.g., Tamoxifen), and finasteride for treatment of benign prostatic hypertrophy (BPH) and prostate cancer. The role of SRMs, which can block the androgen effects on prostate growth, tumor development and/or progression, remains to be determined. Finally, the role of signal transduction cross talk between growth factors and nuclear/orphan receptors may mediate interactions between cell types in the prostate and contribute to stimulation and/or growth of prostate and to tumorigenesis. This remains an important and largely underdeveloped consideration in understanding the development both of normal tissue and of disease, particularly in light of the fact that tumors generally become androgen-independent. Additional studies have suggested a role for environmental factors as well, and thus understanding the overall concept of growth stimuli and growth controls involved in this stage represents an important area in which further investigation is needed. Thus, the specific objectives of this research solicitation include but are not limited to: o Hormonal or growth factor regulation of prostate development, function, growth, or tumor development o Mechanism of action of nuclear hormones and/or peptide hormones or growth factors in the regulation of prostate-specific gene expression o Novel cell culture or transgenic model systems that allow for study in vitro or in vivo of gene expression in prostate or prostate cells o Role(s) of nuclear accessory proteins in regulation of hormone/growth factor action in prostate o Novel factor(s) associated with nuclear hormone action in prostate involved in tumorigenesis o Analogs, agonists, or antagonists of nuclear hormones/growth factors with potential effects on tumor development and/or progression o Orphan nuclear receptors with role(s) in prostate structure, function, or disease development or progression o Structural biology of the androgen receptor (AR) focusing on interactions with other receptor interacting proteins, co-activators or co-repressors, hormone, or hormone response elements o Effects of Selective Receptor Modulators (SRM"s) on prostate o Role(s) of heat shock, or other chaperone, proteins in regulating androgen (and other hormone) function in prostate o Signaling cross-talk between nuclear receptors and/or growth factor or cytokine, and other cell surface receptors, and effects on regulation of prostate gene expression and disease initiation/progression o Use of DNA arrays, bioinformatics approaches to proteomics, or in silico methods of analysis to evaluate gene expression during growth factor or hormone signaling among different cells in the prostate during development, stages of tumor development, or tumor progression o Age-related changes in hormone or growth factor signaling processes and patterns of gene expression that may be involved in the increasing risk of prostate cancer with age o A mechanism of action of nuclear hormones working through non- receptor-mediated events leading to the initiation of cancer in prostate cells o Role(s) of environmental factors that may interact with or influence the effects of hormones and growth factors on prostate growth, development, and/or tumor development INCLUSION OF MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Minorities as Subjects in Clinical Research," which was published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH Guide For Grants and Contracts, Vol. 23, No. 11, March 18, 1994, available on the web at: http://grants.nih.gov/grants/guide/notice-files/not94-100.html. URLS IN NIH GRANT APPLICATIONS OR APPENDICES All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Reviewers are cautioned that their anonymity may be compromised when they directly access an Internet site. LETTER OF INTENT Prospective applicants are asked to submit by February 27, 2001 a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIDDK staff to estimate the potential review workload and plan the review. The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Activities, NIDDK 6707 Democracy Blvd., Room 653 Bethesda, MD 20892-5462 Bethesda, MD 20817 (for express/courier service) Telephone: (301) 594-8885 FAX: (301) 480-3505 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301-710-0267, email: GrantsInfo@nih.gov. The modular grant concept establishes specific modules in which direct costs may be requested as well as a maximum level for requested budgets. Only limited budgetary information is required under this approach. The just-in-time concept allows applicants to submit certain information only when there is a possibility for an award. It is anticipated that these changes will reduce the administrative burden for the applicants, reviewers, and Institute staff. The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants, with the modifications noted below. BUDGET INSTRUCTIONS General instructions for use of the modular grant format include: Modular Grant applications will request direct costs in $25,000 modules, up to a total direct cost request of $225,000 per year for R01 applications, or $100,000 for R21 applications. The total direct costs must be requested in accordance with the program guidelines and the modifications made to the standard PHS 398 application instructions described below, and as noted in the NIH Guide announcement for modular grants (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-046.html): FACE PAGE: Items 7a and 7b should be completed, indicating Direct Costs (in $25,000 increments up to a maximum of $225,000 or $100,000) and Total Costs [Modular Total Direct plus Facilities and Administrative (F&A) costs] for the initial budget period. Items 8a and 8b should be completed indicating the Direct and Total Costs for the entire proposed period of support. o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD: Do not complete Form Page 4 of the PHS 398. It is not required and will not be accepted with the application. o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT: Do not complete the categorical budget table on Form Page 5 of the PHS 398. It is not required and will not be accepted with the application. o NARRATIVE BUDGET JUSTIFICATION: Prepare a Modular Grant Budget Narrative page. (See http://grants.nih.gov/grants/funding/modular/modular.htm for sample pages.) At the top of the page, enter the total direct costs requested for each year. This is not a Form page. o Under Personnel, list ALL project personnel, including their names, percent of effort, and roles on the project. No individual salary information should be provided. However, the applicant should use the NIH appropriation language salary cap and the NIH policy for graduate student compensation in developing the budget request. For Consortium/Contractual costs, provide an estimate of total costs (direct plus facilities and administrative) for each year, each rounded to the nearest $1,000. List the individuals/organizations with whom consortium or contractual arrangements have been made, the percent effort of key personnel, and the role on the project. Indicate whether the collaborating institution is foreign or domestic. The total cost for a consortium/contractual arrangement is included in the overall requested modular direct cost amount. Include the Letter of Intent to establish a consortium. Indirect costs for subcontracts are included in the total costs for the application and should also be in modular form. Provide an additional narrative budget justification for any variation in the number of modules requested. o BIOGRAPHICAL SKETCH: The Biographical Sketch provides information used by reviewers in the assessment of each individual"s qualifications for a specific role in the proposed project, as well as to evaluate the overall qualifications of the research team. A biographical sketch is required for all key personnel, following the instructions below. No more than three pages may be used for each person. A sample biographical sketch may be viewed at: http://grants.nih.gov/grants/funding/modular/modular.htm. - Complete the educational block at the top of the form page, - List position(s) and any honors, - Provide information, including overall goals and responsibilities, on research projects ongoing or completed during the last three years. - List selected peer-reviewed publications, with full citations. o CHECKLIST: This page should be completed and submitted with the application. If the F&A rate agreement has been established, indicate the type of agreement and the date. All appropriate exclusions must be applied in the calculation of the F&A costs for the initial budget period and all future budget years. o The applicant should provide the name and phone number of the individual to contact concerning fiscal and administrative issues if additional information is necessary following the initial review. Applicants should carefully read the specific text of this RFA for budgetary constraints applying to this particular initiative. The RFA label available in the PHS 398 (rev. 4/98) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked. The sample RFA available at: http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been modified to allow for this change. Please note this is in pdf format. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: Center for Scientific Review National Institutes of Health 6701 Rockledge Drive, Room 1040 - MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for express/courier service) At time of submission, two additional copies of the application must be sent to: Chief, Review Branch 6707 Democracy Blvd., Room 653 Division of Extramural Activities, NIDDK Bethesda, MD 20892-5452 Bethesda, MD 20817 (for express/courier service) Applications must be received by March 27, 2001. If an application is received after that date, it will be returned to the applicant without review. Similarly, supplemental documents containing significant revision or additions will not be accepted after that date, unless applicants are notified by the Scientific Review Administrator. The Center for Scientific Review (CSR) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The CSR will not accept any application that is essentially the same as one already reviewed. REVIEW CONSIDERATIONS Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group (special emphasis panel) convened by the NIDDK in accordance with the review criteria stated below. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the National Diabetes and Digestive and Kidney Diseases Advisory Council. Review Criteria The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written comments, reviewer will be asked to discuss the following aspects of the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. o Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? o Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? o Innovation: Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? o Investigator: Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? o Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? In addition to the above criteria, in accordance with NIH policy, all applications will also be reviewed with respect to the following: o Adequacy of plans to include minorities and their subgroups, as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. o The reasonableness of the proposed budget and duration to the proposed research. o The adequacy of the proposed protection of humans, animals, or the environment, to the extent that they may be adversely affected by the project proposed in the application. For applicants from foreign institutions: o Availability of special opportunities for furthering research programs through the use of unusual talent resources, populations, or environmental conditions in other countries which are not readily available in the United States or which provide augmentation of existing U.S. resources. AWARD CRITERIA The anticipated date of award is September 28, 2001. Award criteria that will be used to make award decisions include: o Scientific merit as determined by peer review, o Availability of funds, o Programmatic priorities. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcomed. Direct inquiries regarding programmatic issues relevant to NIDDK to: Ronald Margolis, Ph.D. Senior Advisor, Molecular Endocrinology Division of Diabetes, Endocrinology, and Metabolic Diseases NIDDK 6707 Democracy Blvd. Room 6107 Bethesda, MD 20892-5460 Telephone: (301) 594-8819 FAX: 301-435-6047 E-mail: rm76f@nih.gov Monica Liebert, Ph.D. Director, Basic Science Programs in Urology Division of Kidney, Urology and Hematology NIDDK 6707 Democracy Blvd. Room 623 Bethesda, MD 20892-5460 Telephone: (301) 594-1409 FAX: 301-480-3510 E-mail: LiebertM@extra.niddk.nih.gov Direct inquiries regarding fiscal and administrative matters to: Cheryl Chick Grants Management Specialist Division of Extramural Activities NIDDK Bethesda, MD 20892-5460 Telephone: (301) 594-8825 FAX: (301) 594-3504 E-mail: ChickC@extra.niddk.nih.gov Trude Hilliard Grants Management Specialist Division of Extramural Activities NIDDK Bethesda, MD 20892-5460 Telephone: (301) 594-8859 FAX: (301) 594-3504 E-mail: HilliardT@extra.niddk.nih.gov Direct inquiries regarding programmatic issues relevant to NIA to: Frank Bellino, PhD Deputy Associate Director Endocrinology Program Administrator Biology of Aging Program National Institute on Aging Gateway Bldg., Suite 2C231 Bethesda, MD 20892-9205 Telephone: (301) 496-6402 FAX: (301) 402-0010 E-mail: bellinof@exmur.nia.nih.gov Direct inquiries regarding fiscal and administrative matters to: Crystal Ferguson Grants Management Office National Institute on Aging Gateway Building, Suite 2N212 Bethesda, MD 20892-9205 Telephone: (301) 496-1472 FAX: (301) 402-3672 Email: fergusoc@exmur.nia.nih.gov Direct inquiries regarding programmatic issues relevant to NCI to: Suresh Mohla, Ph.D. Chief, Tumor Biology and Metastasis Branch Division of Cancer Biology National Cancer Institute 6130 Executive Boulevard EPN Suite 5000 Rockville MD 20892-7364 Telephone : (301) 435-1878 FAX : (301) 480-0864 Email: sm82e@nih.gov Direct inquiries regarding fiscal and administrative matters to: Ms. Crystal Wolfrey Lead Grants Management Specialist Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 6120 Executive Blvd., MSC 7150 Rockville, Maryland 20892-7150 Telephone: (301) 496-8634 FAX: (301) 496-8601 Email: wolfreyc@mail.nih.gov Direct inquiries regarding programmatic issues relevant to NIEHS to: Michael E. McClure, Ph.D. Chief, Organs and Systems Toxicology Branch Division of Extramural Research and Training National Institute of Environmental Health Sciences, NIH 111 T.W. Alexander Drive Courier: 79 T.W. Alexander Dr P.O. Box 12233, Mail Drop EC-23 Bldg. 4401, Rm. 3417 Research Triangle Park, North Carolina 27709 RTP. NC 27709 Telephone: (919) 541-5327 FAX: (919) 541-5064 E-Mail: mm461n@nih.gov Direct inquiries regarding fiscal and administrative matters to: Dorothy Duke Division of Extramural Research and Training National Institute of Environmental Health Science Box 12233, MD EC-22 Research Triangle Park, NC 27709 Telephone: (919) 541-1373 FAX: (919) 541-2860 Email: Duke3@niehs.nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.847 for DEM and 93-848 for KUH, No. 93.866 for NIA, No. 93.394 for NCI, and No. 93.113 and 93.866. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under NIH grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The NIH strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the NIH mission to protect and advance the physical and mental health of the American people.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices